André L. Stein

Dr. André L. Stein


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
MFMaria Helena Fermiano
Maria Helena Fermiano
ANAmarith Rodrigues das Neves
Amarith Rodrigues das Neves
FSFernanda da Silva
Fernanda da Silva
Manuella Salustiano Andrade BarrosManuella Salustiano Andrade Barros
Manuella Salustiano Andrade Barros
CVCamila Barbosa Vieira
Camila Barbosa Vieira
TRThalita Riul
Thalita Riul
Leishmaniasis remains a significant global health concern, with current treatments relying on outdated drugs associated with high toxicity, lengthy administration, elevated costs, and drug resistance. Consequently, the urgent need for safer and more effective therapeutic options in leishmaniasis treatment persists. Previous research has highlighted selenium compounds as promising candidates for innovative leishmaniasis therapy. In light of this, a library of 10 selenium-containing diverse compounds was designed and evaluated in this study. These compounds included selenium-substituted indole, coumarin, chromone, oxadiazole, imidazo[1,2-a]pyridine, Imidazo[2,1-b]thiazole, and oxazole, among others. These compounds were screened against Leishmania amazonensis promastigotes and intracellular amastigotes, and their cytotoxicity was assessed in peritoneal macrophages, NIH/3T3, and J774A.1 cells. Among the tested compounds, MRK-106 and MRK-108 displayed the highest potency against L. amazonensis promastigotes with reduced cytotoxicity. Notably, MRK-106 and MRK-108 exhibited IC50 values of 3.97 µM and 4.23 µM, respectively, and most of the tested compounds showed low cytotoxicity in host cells (CC50 > 200 µM). Also, compounds MRK-107 and MRK-113 showed activity against intracellular amastigotes (IC50 18.31 and 15.93 µM and SI 12.55 and 10.92, respectively). In conclusion, the identified selenium-containing compounds hold potential structures as antileishmanial drug candidates to be further explored in subsequent studies. These findings represent a significant step toward the development of safer and more effective therapies for leishmaniasis, addressing the pressing need for novel and improved treatments.

30 October 2025 in Molecules
Verified
Journal Article
Open access
PDF file
TPTais V. de Souza Pinto
Tais V. de Souza Pinto
KSKamilly D. V. P. Sobrinho
Kamilly D. V. P. Sobrinho
MSMaria Eduarda Cardoso da Silva
Maria Eduarda Cardoso da Silva
SOSandynara A. de Oliveira
Sandynara A. de Oliveira
AJAndreia P. V. de Jesus
Andreia P. V. de Jesus
ASAndré L. Stein
André L. Stein
Herein, we report a cobalt-catalyzed cross-coupling of organoselenides with Grignard reagents using simple CoCl2 as the catalyst. This efficient method accommodates a broad scope of selenides, including vinyl, aryl, heteroaryl, and alkynyl derivatives, under mild and ligand-free conditions. Remarkably, the reaction proceeds efficiently without additives and afforded the desired products in moderate to good yields within just 3 h.

21 December 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MFMaria Helena Fermiano
Maria Helena Fermiano
ANAmarith Rodrigues Das Neves
Amarith Rodrigues Das Neves
FSFernanda Da Silva
Fernanda Da Silva
Manuella Salustiano Andrade BarrosManuella Salustiano Andrade Barros
Manuella Salustiano Andrade Barros
CVCamila Barbosa Vieira
Camila Barbosa Vieira
TRThalita Riul
Thalita Riul
Leishmaniasis remains a significant global health concern, with current treatments relying on outdated drugs associated with high toxicity, lengthy administration, elevated costs, and drug resistance. Consequently, the urgent need for safer and more effective therapeutic options in leishmaniasis treatment persists. Previous research has highlighted selenium compounds as promising candidates for innovative leishmaniasis therapy. In light of this, a library of 10 selenium-containing diverse compounds was designed and evaluated in this study. The compounds were subjected to screening against L. amazonensis promastigotes, and their cytotoxicity was assessed in NIH/3T3 cells. Among the tested compounds, MRK-106 and MRK-108 displayed the highest potency against L. amazonensis promastigotes while demonstrating reduced cytotoxicity. Notably, MRK-106 and MRK-108 exhibited IC50 values of 3.97 µM, 4.23 µM, respectively, and most of the tested compounds showed low cytotoxicity in NIH/3T3 cells (CC50 > 200 µM). Although these results are promising, additional investigations focusing on intracellular amastigotes are required to determine the antileishmanial activity of the compounds. In conclusion, the identified selenium-containing compounds hold considerable potential as antileishmanial drug candidates and warrant further exploration in subsequent studies. These findings represent a significant step towards the development of safer and more effective therapies for leishmaniasis, addressing the pressing need for novel and improved treatments.

22 January 2026 in Molecules
Verified
Journal Article
Open access
PDF file
JBJoão M. Brito
João M. Brito
Isabella Moura OliveiraIsabella Moura Oliveira
Isabella Moura Oliveira
CMCassio Augusto de Oliveira Moraes
Cassio Augusto de Oliveira Moraes
ASAlex R. Schneider
Alex R. Schneider
TFTiago E. Elias Allievi Frizon
Tiago E. Elias Allievi Frizon
Sumbal SabaSumbal Saba
Sumbal Saba
Herein, we disclose a highly efficient pathway toward 3-selenylated chromone derivatives via electrosynthesis domino C(sp2)-H bond selenylation/cyclization/deamination of 2-hydroxyaryl enaminones with diselenides. This method showed mild conditions, easy operation, a wide substrate scope, and good functional group tolerance. Furthermore, this electrosynthesis strategy was amenable to scaling up the reaction. Additionally, the preliminary experiments revealed that this reaction probably proceeded via a cation pathway instead of a radical pathway.